Combination Therapy for MRSA Bacteremia —Not Ready for Prime Time

Enhanced infection control efforts have helped reduce the rate of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia over the past decade, but the decline has stalled in recent years, and associated mortality remains steady at 20% to 25%. In terms of both clinical burden and absolute number of patients, MRSA bacteremia remains a common and highly morbid infection. While clinical practice guidelines, evidence-based management algorithms, and infectious diseases consultation can contribute to improved patient outcomes, a substantial proportion of patients still experience treatment failures. Vancomycin or daptomycin remain the preferred treatment for MRSA bacteremia, but the search for safer and more effective options continues.
Source: JAMA - Category: General Medicine Source Type: research